Company: ENTXW
Filing Date: 2025-05-30
Form Type: S-3
Source: 0001178913-25-002025
Chunk: 31

Company: Entera Bio Ltd.
Filing Date: 2025-05-30
Form: S-3
Chunk 31
---
15 for additional information regarding the compensation to be paid to Leerink Partners. In connection with the sale of the ordinary shares on our behalf, Leerink Partners will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation to Leerink Partners will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act. Our ordinary shares trade on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “ENTX”. On May 29, 2025, the closing price for our ordinary shares on Nasdaq was $1.82 per share. Investing in our ordinary shares involves risks. See “Risk Factors” beginning on page S-4 of this prospectus and in the reports we file with the Securities and Exchange Commission (the “SEC”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), incorporated by reference in this prospectus before making a decision to invest in our ordinary shares. Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. Leerink Partners , 2025 TABLE OF CONTENTS Page

| About This Prospectus                                            | S-1  |
| Prospectus Summary                                               | S-2  |
| The Offering                                                     | S-3  |
| Risk Factors                                                     | S-4  |
| Cautionary Note Regarding Forward-Looking Statements             | S-7  |
| Use of Proceeds                                                  | S-9  |
| Dividend Policy                                                  | S-10 |
| Dilution                                                         | S-11 |
| Description of Ordinary Shares                                   | S-12 |
| Plan of Distribution                                             | S-15 |
| Service of Process and Enforcement of Judgments                  | S-16 |
| Material U.S. Federal Income Tax Considerations for U.S. Holders | S-17 |
| Legal Matters                                                    | S-21 |
| Experts                                                          | S-21 |
| Where You Can Find More Information                              | S-21 |
| Incorporation of Certain Documents By Reference                  | S-22 |

ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the SEC, using a “shelf” registration process. Under this shelf registration process, we may from time to time sell ordinary shares, debt